Analysts Offer Predictions for SNTI FY2030 Earnings

Senti Biosciences, Inc. (NASDAQ:SNTI) – Stock analysts at HC Wainwright issued their FY2030 earnings estimates for shares of Senti Biosciences in a research note issued on Friday, March 27th. HC Wainwright analyst E. Bodnar anticipates that the company will earn ($0.07) per share for the year. The consensus estimate for Senti Biosciences’ current full-year earnings is ($14.54) per share.

Senti Biosciences (NASDAQ:SNTI) last announced its quarterly earnings data on Friday, March 27th. The company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.10). The business had revenue of $0.02 million for the quarter, compared to analyst estimates of $1.00 million.

A number of other research firms have also recently issued reports on SNTI. Weiss Ratings restated a “sell (e+)” rating on shares of Senti Biosciences in a report on Thursday, January 22nd. Wall Street Zen upgraded Senti Biosciences from a “strong sell” rating to a “hold” rating in a research note on Saturday. Finally, Chardan Capital decreased their target price on Senti Biosciences from $13.00 to $11.00 and set a “buy” rating for the company in a research report on Monday. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.50.

Senti Biosciences Stock Performance

Shares of NASDAQ SNTI opened at $0.77 on Monday. The business’s 50 day moving average price is $0.94 and its 200-day moving average price is $1.38. Senti Biosciences has a fifty-two week low of $0.77 and a fifty-two week high of $5.10. The company has a market cap of $20.29 million, a price-to-earnings ratio of -0.24 and a beta of 2.12.

Institutional Trading of Senti Biosciences

A number of large investors have recently modified their holdings of the company. Armistice Capital LLC bought a new position in Senti Biosciences in the second quarter worth approximately $1,883,000. Geode Capital Management LLC raised its position in Senti Biosciences by 395.6% during the 2nd quarter. Geode Capital Management LLC now owns 147,314 shares of the company’s stock valued at $311,000 after purchasing an additional 117,588 shares in the last quarter. Citadel Advisors LLC bought a new stake in Senti Biosciences during the 3rd quarter valued at $117,000. Virtu Financial LLC purchased a new stake in shares of Senti Biosciences in the 4th quarter worth $46,000. Finally, Jane Street Group LLC purchased a new stake in shares of Senti Biosciences in the 4th quarter worth $40,000. Hedge funds and other institutional investors own 25.70% of the company’s stock.

Senti Biosciences Company Profile

Senti Biosciences (NASDAQ:SNTI) is a clinical-stage synthetic biology company focused on engineering next-generation cell therapies. The company’s platform leverages modular genetic circuits to sense disease signals and precisely control cellular functions, with the goal of improving safety and efficacy in oncology and immune-mediated diseases.

Senti’s core technologies include its SENTINEL circuit platform and SNIP receptor system, which enable programmable sensing of molecular cues and context-dependent payload release.